Crescent Biopharma, Inc. vs C4 Therapeutics, Inc. — Valuation Comparison 2026
Access all valuation models for CBIO vs CCCC — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.
Access Full Analysis — From $27/mo →CCCC scores higher with a 5.3/10 quality rating vs CBIO's 5.3/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.
Comparing Crescent Biopharma, Inc. (CBIO) and C4 Therapeutics, Inc. (CCCC) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.
CBIO currently trades at $21.47 with a QOC of 5.3/10, while CCCC trades at $3.66 with a QOC of 5.3/10.
Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).